The Technical Analyst
NeuroPace, Inc. [NPCE]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
NeuroPace, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.26% $13.30
America/New_York / 7 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 381.97 mill |
| EPS: | -1.270 |
| P/E: | -10.47 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 28.72 mill |
| Avg Daily Volume: | 0.109 mill |
| RATING 2024-05-07 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.47 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.05x |
| Company: PE -10.47 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 12.35 - 14.25 ( +/- 7.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-01 | Orbimed Advisors Llc | Sell | 15 690 | Common Stock |
| 2024-05-02 | Orbimed Advisors Llc | Sell | 8 842 | Common Stock |
| 2024-05-03 | Orbimed Advisors Llc | Sell | 4 674 | Common Stock |
| 2024-04-24 | Orbimed Advisors Llc | Sell | 1 781 | Common Stock |
| 2024-04-19 | Orbimed Advisors Llc | Sell | 18 253 | Common Stock |
| INSIDER POWER |
|---|
| 15.18 |
| Last 97 transactions |
| Buy: 3 318 075 | Sell: 1 148 594 |
Forecast:
16:00 - $13.34
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $13.34
Forecast 2: 16:00 - $13.34
Forecast 3: 16:00 - $13.34
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.30 (-1.26% ) |
| Volume | 0.0464 mill |
| Avg. Vol. | 0.109 mill |
| % of Avg. Vol | 42.70 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NPCE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:32 | buy | $16.95 | N/A | Active |
|---|
NPCE
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Latest Press Releases
2024-04-17 16:05:00 - Press Release
Neuropace To Report First Quarter 2024 Financial Results On May 8, 2024
Mountain view, calif., april 17, 2024 (globe newswire) -- neuropace, inc. (nasdaq: npce), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on wednesday, may 8, 2024. the company's management will webcast a corresponding conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
2024-03-27 16:05:00 - Press Release
Neuropace To Present At The Needham 23rd Annual Healthcare Conference
Mountain view, calif., march 27, 2024 (globe newswire) -- neuropace, inc. (nasdaq: npce), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the needham 23rd annual healthcare conference, taking place virtually from april 8-11.
2024-03-05 16:05:00 - Press Release
Neuropace Announces Record Full Year 2023 Revenue Of $65.4 Million
-- revenue increased to $18.0 million in q4 2023, a 41% increase over q4 2022 -- -- revenue increased to $65.4 million in 2023, a 44% increase over 2022 --
2024-02-15 16:05:00 - Press Release
Neuropace To Report Fourth Quarter And Full Year 2023 Financial Results On March 5, 2024
Mountain view, calif., feb. 15, 2024 (globe newswire) -- neuropace, inc. (nasdaq: npce), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year 2023 after market close on tuesday, march 5, 2024. the company's management will webcast a corresponding conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
2024-01-08 07:03:00 - Press Release
Neuropace Announces Preliminary Unaudited Revenue For Fourth Quarter And Full Year 2023 And Provides Business Updates
Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for q4 2023 and between $64.9 million and $65.4 million for full year 2023
Latest News
2024-04-17 16:05:00 - GlobeNewsWire
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2024-03-27 16:05:00 - GlobeNewsWire
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11.
2024-03-05 21:29:08 - Seeking Alpha
NeuroPace, Inc. (NPCE) Q4 2023 Earnings Call Transcript
2024-03-05 14:00:00 - InvestorPlace
Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio
One of the best stocks for financial freedom over the past 30 years is Monster Beverage (NASDAQ: MNST ). Between Feb. 14, 1994, and Feb. 14, 2024, the energy drink maker's stock appreciated around 200,000%.
2024-02-15 16:05:00 - GlobeNewsWire
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Tuesday, March 5, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-12-19 16:30:00 - GlobeNewsWire
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30am PT (10:30am ET) on Thursday, January 10, 2024, in San Francisco, CA as well as host investor meetings prior to and during the conference.
2023-11-21 08:00:00 - GlobeNewsWire
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced will present at the Piper Sandler 35th Annual Healthcare Conference, taking place November 28-30 in New York, NY.
2023-11-06 21:44:06 - Seeking Alpha
NeuroPace, Inc. (NPCE) Q3 2023 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Michael Polark - Wolfe Research Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, greetings and welcome to the NeuroPace, Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
2023-10-16 17:01:00 - GlobeNewsWire
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2023 after market close on Monday November 6, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-09-20 16:05:00 - GlobeNewsWire
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced participation in a fireside chat discussion at the upcoming 2023 Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023, at 1:15 p.m. ET in New York, New York.